Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • Warm AIHA
      • COVID-19
      • IRAK1/4
      • RIPK1
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Oct 02, 2019 7:00am EDT

Rigel Secures Credit Facility for Up to $60 Million

Sep 23, 2019 7:30am EDT

Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

Aug 28, 2019 7:30am EDT

Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference

Aug 06, 2019 4:01pm EDT

Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update

Jul 30, 2019 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results

Jun 13, 2019 7:30am EDT

Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)

May 31, 2019 7:30am EDT

Rigel to Present at Jefferies 2019 Healthcare Conference

May 16, 2019 7:30am EDT

Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia

May 07, 2019 4:01pm EDT

Rigel Announces First Quarter 2019 Financial Results and Provides Company Update

Apr 30, 2019 7:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update

  • Previous
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …34
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2022 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin